Decades-Old Compound Burns Fat Without Muscle Loss and Boosts GLP-1 Drug Results
TOFA raised energy expenditure 18% in obese mice, cut body fat, preserved muscle, and amplified GLP-1 drug effects — a fresh metabolic obesity strategy.
Summary
Researchers at UC Berkeley have found that a compound called TOFA, first discovered in the 1970s, can help obese mice burn significantly more energy without eating less. In animal experiments, TOFA increased energy use by up to 18%, reduced body fat while preserving lean muscle mass, and improved blood sugar, triglycerides, and fatty liver disease. Unlike GLP-1 drugs such as Ozempic, which work by suppressing appetite, TOFA targets the body's energy expenditure side of the equation. It works by blocking fat production and simultaneously activating cellular receptors that encourage cells to burn fat for fuel. When combined with GLP-1 medications, results were even stronger. Researchers say this dual-mechanism approach could eventually complement or enhance existing obesity therapies.
Detailed Summary
Obesity treatment has been transformed by GLP-1 drugs like Ozempic and Wegovy, but these medications carry a significant drawback: by suppressing appetite and food intake, they can lead to muscle loss, nutritional deficiencies, and potentially increased frailty risk — a serious concern for long-term healthspan. Researchers at UC Berkeley believe they have found a complementary approach that targets the other side of the metabolic equation: energy expenditure rather than calorie intake.
Published in Science Advances, the study examines a compound called TOFA (5-tetradecyloxy-2-furoic acid), originally discovered in the 1970s as an ACC inhibitor — a class of molecules that block the body's production of lipids like cholesterol and triglycerides. Most ACC inhibitors stalled in clinical development because they paradoxically raised triglyceride levels, increasing cardiovascular risk. TOFA appears to sidestep this problem through an additional mechanism: it activates PPARα and PPARδ receptors, which switch on genes that prompt cells to absorb and burn fat for fuel.
In obese mice, TOFA raised energy expenditure by as much as 18% without increasing physical activity or body temperature — meaning the extra calorie burn was driven purely by metabolic acceleration. Body fat declined significantly, while lean muscle mass was preserved. Blood sugar control, insulin sensitivity, triglyceride levels, and markers of fatty liver disease all improved. Critically, TOFA did not produce the triglyceride spike seen with other ACC inhibitors, likely because its dual action on both lipid production and fat oxidation creates a balanced metabolic effect.
Perhaps most compelling for clinical translation, combining TOFA with GLP-1 drugs produced stronger results than either treatment alone, suggesting a genuine synergy between appetite suppression and enhanced energy expenditure.
Caveats are important: all data come from mouse models, and TOFA has not been tested in human clinical trials. Translating metabolic findings from rodents to people is notoriously difficult. Dose, safety profile, and long-term effects in humans remain entirely unknown. Nonetheless, the mechanism is biologically plausible and the muscle-preserving effect directly addresses one of the most pressing limitations of current obesity pharmacology.
Key Findings
- TOFA increased energy expenditure by up to 18% in obese mice without raising physical activity or body temperature.
- Obese mice lost body fat with no significant reduction in lean muscle mass — a key advantage over GLP-1 drugs alone.
- TOFA improved insulin sensitivity, blood sugar, triglycerides, and fatty liver disease markers in treated mice.
- Combining TOFA with GLP-1 medications produced stronger metabolic results than either treatment alone.
- Unlike other ACC inhibitors, TOFA did not raise triglyceride levels, potentially avoiding cardiovascular risk.
Methodology
This is a news report summarizing a peer-reviewed study published in Science Advances (August 21, 2026) from UC Berkeley. Evidence is based on preclinical mouse experiments; no human trial data are available yet. Science Advances is a reputable, high-impact open-access journal published by AAAS.
Study Limitations
All findings are from obese mouse models; rodent metabolism differs substantially from human metabolism and translation often fails. Human safety, effective dosing, and long-term outcomes for TOFA are entirely unknown. Readers should await Phase I/II human trial data before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: